198 related articles for article (PubMed ID: 9240625)
1. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
2. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
4. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
5. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
6. GnRH-agonists in fertility preservation.
Blumenfeld Z
Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):523-8. PubMed ID: 18971681
[TBL] [Abstract][Full Text] [Related]
7. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
8. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.
Oktay K; Sönmezer M; Oktem O; Fox K; Emons G; Bang H
Oncologist; 2007 Sep; 12(9):1055-66. PubMed ID: 17914075
[TBL] [Abstract][Full Text] [Related]
9. Fertility after treatment for Hodgkin's disease.
Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
[TBL] [Abstract][Full Text] [Related]
10. Ovarian rescue/protection from chemotherapeutic agents.
Blumenfeld Z
J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
[TBL] [Abstract][Full Text] [Related]
11. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients.
Huser M; Crha I; Ventruba P; Hudecek R; Zakova J; Smardova L; Kral Z; Jarkovsky J
Hum Reprod; 2008 Apr; 23(4):863-8. PubMed ID: 18258763
[TBL] [Abstract][Full Text] [Related]
12. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
Blumenfeld Z; von Wolff M
Hum Reprod Update; 2008; 14(6):543-52. PubMed ID: 18824495
[TBL] [Abstract][Full Text] [Related]
13. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
Castelo-Branco C; Nomdedeu B; Camus A; Mercadal S; Martínez de Osaba MJ; Balasch J
Fertil Steril; 2007 Mar; 87(3):702-5. PubMed ID: 17173900
[TBL] [Abstract][Full Text] [Related]
14. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
[TBL] [Abstract][Full Text] [Related]
15. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
16. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
Blumenfeld Z
Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
[TBL] [Abstract][Full Text] [Related]
17. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
Franke HR; Smit WM; Vermes I
Gynecol Endocrinol; 2005 May; 20(5):274-8. PubMed ID: 16019373
[TBL] [Abstract][Full Text] [Related]
18. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients.
Nitzschke M; Raddatz J; Bohlmann MK; Stute P; Strowitzki T; von Wolff M
Arch Gynecol Obstet; 2010 Jul; 282(1):83-8. PubMed ID: 19967405
[TBL] [Abstract][Full Text] [Related]
19. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
20. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.
Beck-Fruchter R; Weiss A; Shalev E
Hum Reprod Update; 2008; 14(6):553-61. PubMed ID: 18820006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
